health
Access to twice-yearly HIV prevention drug remains contested
2,000participants
The 2024 lenacapavir clinical trial involved more than 2,000 young women.
Lenacapavir has shown strong results in HIV prevention and has been recommended by the WHO, but MSF says licensing, pricing and supply arrangements could limit access in several countries and humanitarian settings.
1 sourceAl JazeeraUpdated
Claims
Support what holds up. Dispute what doesn't.
No participant who received lenacapavir contracted HIV in a 2024 clinical trial involving young women in South Africa and Uganda.
“no participants who received lenacapavir contracted HIV”
- 2,000participants
The 2024 lenacapavir clinical trial involved more than 2,000 young women.
“involving more than 2,000 young women”
The World Health Organization recommended long-acting injectable lenacapavir as an additional form of PrEP.
“The World Health Organization has recommended the long-acting injectable as an additional form of pre-exposure prophylaxis”